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Abstract 
A novel approach to 3-oxo-γ-carbolines was worked out starting from methyl 
indol-2-ylacetate via a gramine derivative. After quaternization, ammonia and 
4-methoxybenzylamine could be inserted giving appropriate 3-oxo-γ-carbolines. 
Condensation with 2-chlorobenzaldehyde under microwave irradiation gave a 
4-(2-chlorobenzyl)-3-oxo-γ-carboline. N-methylation lead to a product with very 
promising antifungal and cytotoxic activities. 
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Introduction 
Natural products are a important source for innovative drugs, and a very large number of 
marketed drugs consist of natural products or derivatives thereof [1]. Among the bioactive 
natural products alkaloids play a major role, and β-carboline alkaloids 
(pyrido[3,4-b]indoles) have attracted great interest due to their broad spectrum of 
biological activities [2].  
In the course of our recent investigations on bioactive compounds from natural sources, 
we had a strong focus on 1-oxo-β-carboline alkaloids and synthetic analogues thereof. So 
we worked out efficient strategies for the construction of 1-oxo-β-carbolines [3–6] and 
hybrids between 1-oxo-β-carbolines and other alkaloids [7]. 
Among the most fascinating compounds from our recent investigations was the 1-oxo-
β-carboline alkaloid bauerine C (A) [8], which exhibits significant cytotoxic and antiviral 60  U. Wollein and F. Bracher:   
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activities. The first total synthesis of this alkaloid was worked out by our group [5], and 
opens the opportunity for further analysis of structure-activity relationships. Meanwhile, 
numerous 1-oxo-β-carbolines have been reported to exhibit significant biological activities 
like inhibition of protein kinases [9–11]. 
As a useful supplement to the investigations on 1-oxo-β-carbolines mentioned above, we 
intended to work out a synthetic approach to the isomeric 3-oxo-γ-carbolines 
(pyrido[4,3-b]indol-3-ones, B).  
The γ-carbolines have found only poor application in drug therapy until now, presumably 
due to their poor synthetic availability. Among the few prominent examples are latrepirdine 
(former name: dimebolin; C), a candidate for treatment of Huntington disease [12], the 
antihistaminic mebhydrolin (D) [13], and the serotonin receptor antagonist alosetron (E) 
[14] (Figure 1). An overview over other biological activities of γ-carbolines is given in 
reference [15]. 
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Fig. 1.   Bauerine C (A), 3-oxo-γ-carboline (B), latrepirdine (C), mebhydrolin (D), 
alosetron (E), arylidene oxindoles (F) 
Until now only very few approaches to 3-oxo-γ-carbolines have been worked out, and the 
known strategies only lead to products with additional substituents at C-1 [16] or C-4 
[17, 18]. 
Here we report on a novel approach to 3-oxo-γ-carbolines and further functionalizations, 
ending up with the discovery of a new cytotoxic lead structure. Homologous tetrahydro-
azepino[4,5-b]indolones [19] have been reported earlier, but no data on biological activities 
of these products are available.  
Results and Discussion 
A retrosynthetic analysis suggested performing the construction of the target 3-oxo-γ-
carboline ring system by a final ring closure via lactamization; hence an indole bearing a  Pyrido[4,3-b]indol-3-ones with Cytotoxic Activity  61 
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(derivatized) carboxymethyl group at C-2, and an aminomethyl group at C-3 was selected 
as precursor. 
Methyl indol-2-ylacetate (1) is readily available by homolytic alkylation of indole with methyl 
iodoacetate promoted by hydrogen peroxide and iron(II) sulfate following Baciocchi’s 
procedure [20]. Subsequent aminomethylation with N,N-dimethylmethyleneiminium 
chloride (Eschenmoser’s salt) [21] gave the gramine derivative 2 in good yield. This 
compound was treated with methyl iodide in tetrahydrofuran to give a quaternary 
intermediate, which upon treatment with aqueous ammonia gave the target tricyclic lactam 
3a in 51% yield. In this reaction ammonia performs a nucleophilic substitution at the 
quaternary ammonium group under extrusion of trimethylamine; the intermediate primary 
amine then undergoes spontaneous lactamization with the ester group. In an analogous 
manner, the quaternary ammonium salt was reacted with 4-methoxybenzylamine to give 
the N-benzylated lactam 3b in 34% yield. 
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Sch. 1.   a) N,N-dimethylmethyleneiminium chloride, dichloromethane, r.t., 1 h (61%); b) 
iodomethane, tetrahydrofuran, r.t., 1 h; c) conc. ammonia, r.t., 12 h (51% over 
2 steps); d) 4-methoxy-benzylamine (neat), r.t., 12 h (34% over 2 steps). 
Since the methylene group at C-4, next to the lactam carbonyl group in 3a, should be 
slightly CH-acidic, we intended to perform some condensation reactions at this position. 
Upon reaction with aromatic aldehydes α-arylidene lactams should result. The target 
compounds show similarity to arylidene oxindoles (F; Figure 1), which are known as 
antitumor agents targeting various kinases (e.g. sunitinib [22]), and have very recently 
been described as sirtuin inhibitors by our group [23]. First attempts at condensation of 
lactam 3a with aromatic aldehydes by refluxing the components in ethanol or toluene in 
the presence of bases (piperidine, pyrrolidine) following Sun’s methodology [24] gave 
disappointing results; no conversion was observed at all. Finally we were able to perform 
the Knoevenagel-type condensation of 3a with 2-chlorobenzaldehyde by using Ding’s 
protocol [25]. Both starting materials were loaded on a commercial potassium fluoride on 
aluminium oxide support, and the resulting solid was heated in a microwave reactor 
without solvent for 8 min (maximum temperature: 150 °C). However, the condensation 
product obtained in 20% yield did not have the expected arylidenelactam structure 5, but 
was identified as the tautomeric 4-(2-chlorobenzyl)-3-oxo-γ-carboline 4. The structure was 
confirmed unambiguously by NMR experiments. In a HMBC experiment (which detects 
2J 
and 
3J C-H couplings) the methylene protons showed 6 couplings, in accordance with 
structure 4; tautomer 5 would give only 4 couplings in this experiment. NOE experiments 
showed the physical proximity of the methylene protons and 6’-H at the chlorophenyl 
residue, as well as the proximity of 1-H and 9-H of the tricyclic core. Unfortunately, 62  U. Wollein and F. Bracher:   
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analogous condensations with other aromatic aldehydes (benzaldehyde, 4-fluoro-
benzaldehyde, 3,4,5-trimethoxybenzaldehyde) gave only very poor conversions (<10%), 
and the purification of the products was difficult. 
Finally, we reacted the 4-(2-chlorobenzyl)-3-oxo-γ-carboline  4  with iodomethane and 
potassium tert-butoxide and obtained the 2,5-dimethyl derivative 6. 
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Sch. 2.   e) 2-chlorobenzaldehyde, potassium fluoride/aluminium oxide, microwave 
irradiation (20%); f) iodomethane, potassium tert-butoxide, dimethyl sulfoxide, 
80 °C, 2 h (24%). 
The new compounds were submitted to a screening for cytotoxic activity in a standard 
MTT assay [26] and an agar diffusion assay for detection of antibacterial and antifungal 
activities. The results are shown in Table 1. 
These preliminary screenings clearly indicate that compound 6  has by far the highest 
biological activities. Its antibacterial activities are significant, but lower than those of the 
reference antibiotic tetracycline hydrochloride, the antifungal activities against Candida 
glabrata and Aspergillus niger are in the same range as those of clotrimazole. And finally, 
this chlorobenzyl 3-oxo-γ-carboline shows cytotoxic activity comparable to cisplatin. The 
enormous enhancement of biological activities caused by the introduction of both N-methyl 
groups (4 → 6) is noteworthy. 
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Tab. 1.   Results of the screenings for cytotoxicity (“MTT”; IC50 values against HL 60 cells 
in μM) and for activity against gram-negative bacteria (Escherichia coli, “E.coli”.; 
Pseudo-monas antimicrobia, “Pseud”), gram-positive bacteria (Staphylococcus 
equorum, “Staph”; Streptococcus entericus, “Strept”), yeasts (Yarrowia 
lipolytica, “Yarr”; Candida glabrata, “Cand”), the dermatophyte Hyphopichia 
burtonii (“Hyph”) and the mould Aspergillus niger (“Asp”) (diameters of the 
zones of inhibition in mm). Reference substances: Cisplatin (“CisP”) for the MTT 
assay; tetracycline hydrochloride (“Tet”) for antibacterial, and clotrimazole 
(“Clo”) for antifungal activity. 
# MTT  E.coli  Pseud Staph Strept Yarr Cand Hyph  Asp
2  >100 0  0  0  0  0  0  0  0 
3a  >100 0  10  0  8  0  11  0  10 
3b  36 0  0  0  0  0 0  0 0 
4  >100 0  0  0  0  0  0  0  0 
6  5 17 17 15  8 10  18 0  20 
CisP  5              
Tet   30 32 44 24        
Clo         20  18  16  20 
 
In conclusion, we have worked out a new synthetic approach to the until now poorly 
investigated class of 3-oxo-γ-carbolines, and have identified compound 6 as a very 
interesting lead compound for further development. But for being able to prepare a large 
number of additional analogues for screening and analysis of structure-activity 
relationships, we will have to work out an optimized protocol for the introduction of benzyl 
and related moieties at C-4. Work is in progress to find efficient methodologies. 
Experimental 
Microwave reactor: CEM Discover. Column chromatography was performed on Kieselgel 
60 (230–400 mesh), the solvent ratios are given as v/v. All solvents were dried over 
appropriate drying agents. Melting points: Büchi Melting point B-540, uncorrected. IR-
Spectra: Jasco FT-IR-410. High resolution and mass spectra were obtained on a Hewlett 
Packard 5989 A and a Jeol M Station 700. 
1H and 
13C NMR spectra were recorded on a 
Jeol JNMR-GSX 400 or a Jeol JNMR-GSX 500, using TMS as internal standard. 
Elemental analyses were performed on a Varian Vario EL. 
Methyl {3-[(dimethylamino)methyl]-1H-indol-2-yl}acetate (2) 
To a solution of methyl indol-2-ylacetate (1, 1.48 g, 7.82 mmol) in 15 ml dichloromethane 
was added N,N-dimethylmethyleneiminium chloride (1.00 g, 10.2 mmol). The mixture was 
stirred at r.t. for 1 h, and after addition of 30 ml water stirring was continued for 3 min. The 
mixture was adjusted to pH 10 with 3 N sodium hydroxide solution and extracted with 
dichloromethane/methanol (95:5; 3 × 20 ml). The combined organic layers were washed 
with brine (50 ml), dried over magnesium sulfate, and evaporated in vacuo. Purification 
was performed by chromatography (ethyl acetate, hexane, N-ethyl-N,N-dimethylamine, 
80:20:2) to yield 2 as red crystals (897 mg, 61 %); mp 108 °C. 
1H NMR (CD2Cl2): δ = 8.74 
(br s, 1 H, NH), 7.60 (d, J = 8.0 Hz, 1 H, 4-H), 7.34 (d, J = 8.0 Hz, 1 H, 7-H), 7.13 (ddd, 64  U. Wollein and F. Bracher:   
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J = 1.0, 7.0, 8.0 Hz, 1 H, 6-H), 7.06 (ddd, J = 1.0, 7.0, 8.0 Hz, 1 H, 5-H), 3.91 (s, 2 H, CH2), 
3.73 (s, 3  H, OCH3), 3.56 (s, 2  H, CH2N), 2.22 (s, 6  H, N(CH3)2). 
13C NMR (CD2Cl2): 
δ = 171.4, 135.9, 129.5, 129.0, 122.0, 119.8, 119.3, 111.0 (2 C), 53.6 (2 C), 52.6, 45.4, 
31.9. MS (EI, 70 eV): m/z (%) = 246 (12, M
+), 201 (100), 169 (76), 142 (74). IR (KBr) ν, 
cm
−1: 3408, 2862, 1737, 1456, 1206, 1170, 992. Elemental analysis: Calcd. for 
C14H18N2O2: C, 68.27; H, 7.37; N, 11.37; found: C, 68.76; H, 7.41; N, 11.42. 
1,2,4,5-Tetrahydro-3H-pyrido[4,3-b]indol-3-one (3a) 
To a solution of gramine derivative 2 (1.90 g, 7.71 mmol) in 60 ml tetrahydrofuran was 
added iodomethane (10.9  g, 77.1  mmol). After stirring at r.t. for 1  h the solvent was 
removed under reduced pressure, the residue was dissolved in 180  ml of aqueous 
ammonia solution (30 %). This mixture was stirred at r.t. for 12 h. Then brine (50 ml) was 
added and the mixture was extracted with dichloromethane/methanol (95:5; 3 × 75 ml). 
The combined organic layers were evaporated in vacuo. The residue was digested with 
cold dichloromethane (20 ml), the remaining residue was collected and crystallized from 
ethyl acetate to give 3a as a yellow powder (470 mg, 51 %); mp 303 °C. 
1H NMR (DMSO-
d6): δ = 10.92 (br s, 1 H, 5-H), 8.05 (br s, 1 H, 2-H), 7.40 (d, J = 8.0 Hz, 1 H, 9-H), 7.32 (d, 
J = 8.0 Hz, 1 H, 6-H), 7.06 (ddd, J = 1.0, 7.1, 8.0 Hz, 1 H, 7-H), 6.98 (ddd, J = 1.0, 7.1, 
8.0 Hz, 1 H, 8-H), 4.46 (m, 2 H, 1-H), 3.54 (t, J = 3.6 Hz, 2 H, 4-H). 
13C NMR (DMSO-d6): 
δ = 167.9, 136.8, 129.9, 124.8, 121.1, 118.8, 117.7, 111.2, 102.7, 40.6, 30.4. MS (EI, 70 
eV): m/z (%) = 186 (100, M
+), 143 (86). IR (KBr) ν, cm
−1: 3187, 3052, 1666, 1629, 1010, 
834. Elemental analysis: Calcd. for C11H10N2O: C, 70.95; H, 5.41; N, 15.04; found: C, 
70.74; H, 5.29; N, 14.78. 
2-(4-Methoxybenzyl)-1,2,4,5-tetrahydro-3H-pyrido[4,3-b]indol-3-one (3b) 
To a solution of gramine derivative 2 (2.30 g, 9.33 mmol) in 60 ml tetrahydrofuran was 
added iodomethane (13.2  g, 93.3  mmol). After stirring at r.t. for 1  h the solvent was 
removed under reduced pressure, and the residue was dissolved in 50  ml 4-
methoxybenzylamine, and the mixture was stirred vigorously at r.t. for 12 h. Then brine 
(100 ml) was added and the mixture was extracted with dichloromethane/methanol (95:5; 
3 × 50 ml). The combined organic layers were washed with 2 N hydrochloric acid (4 × 
50 ml), dried over sodium sulfate and evaporated in vacuo. The residue was purified by 
chromatography (ethyl acetate, hexane, N-ethyl-N,N-dimethylamine, 80:20:2), followed by 
crystallization from methanol to yield 3b as colourless crystals (964 mg, 34 %); mp 183 °C. 
1H NMR (DMSO-d6): δ = 10.97 (br s, 1 H, 5-H), 7.34 (d, 1 H, J = 8.0 Hz, 9-H), 7.27 (dt, 2 
H, J = 9.1, 2.5 Hz, 2'-H, 6'-H), 7.06 (ddd, 1 H, J = 8.0, 7.1, 1.0 Hz, 7-H), 6.96 (ddd, 1 H, J = 
8.0, 7.1, 1.0 Hz, 8-H), 6.90 (dt, 2 H, J = 9.1, 2.5 Hz, 3'-H, 5'-H), 4.69 (s, 2 H, CH2), 4.51 (t, 
2 H, J = 3.5 Hz, 1-H), 3.75 (t, 2 H, J = 3.5 Hz, 4-H), 3.72 (s, 3 H, OCH3). 
13C NMR (DMSO-
d6): δ = 166.0, 158.7, 136.6, 129.6, 129.5, 129.3 (2 C), 124.6, 121.2, 119.0, 117.6, 114.1 
(2 C), 111.3, 102.3, 55.2, 49.1, 45.0, 30.9. MS (EI, 70 eV): m/z (%) = 306 (48, M
+), 144 
(100). IR (KBr) ν, cm
−1: 3243, 2927, 2834, 1619, 1511, 1457, 1369, 1326, 1245, 1176, 
1033, 744. Elemental analysis: Calcd. for C19H18N2O2: C, 74.49; H, 5.92; N, 9.14; found: C, 
74.43; H, 5.96; N, 9.01. 
4-(2-Chlorobenzyl)-2,5-dihydro-3H-pyrido[4,3-b]indol-3-one (4) 
To a solution of the tetrahydropyrido[4,3-b]indol-3-one 3a (200  mg, 1.08  mmol) and 2-
chlorobenzaldehyde (151 mg, 1.08 mmol) in 20 ml acetonitrile 1.70 g potassium fluoride  Pyrido[4,3-b]indol-3-ones with Cytotoxic Activity  65 
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on alumimum oxide (about 5.5 mmol fluoride/g; Aldrich) was added, and the suspension 
was stirred at r.t. for 5 min. Then the solvent was removed in vacuo, and the finely 
powdered residue placed in a microwave vial and irradiated at an energy impact of 60 W 
for 8 min. During this time the mixture reached a maximum temperature of 150 °C. After 
cooling the mixture was extracted with 20 ml acetonitrile and 20 ml dichloro-
methane/methanol (95:5). The combined organic layers were evaporated and the residue 
purified by chromatography (chloroform, ethanol, 9:1) to yield 5 as brownish-yellow 
crystals (67 mg, 20%); mp 216 °C. 
1H NMR (DMSO-d6): δ = 10.9 (br s, 1 H, 5-H), 8.29 (s, 
1 H, 1-H), 7.90 (d, 1 H, J = 7.7 Hz, 9-H), 7.47 (dd, 1 H, J = 7.8, 1.5 Hz, 3'-H), 7.25 (t, 1 H, 
J = 7.7 Hz, 7-H), 7.21 (ttt, 1 H, 7.8, 6.3, 1.5 Hz, 4'-H), 7.18 (d, 1 H, J = 7.7 Hz, 6-H), 7.14 
(ddd, 1 H, J = 7.8, 6.3, 1.5 Hz, 5'-H), 7.07 (t, 1 H, J = 7.7 Hz, 8-H), 6.79 (dd, 1 H, J = 7.8, 
1.5 Hz, 6'-H), 3.98 (s, 2 H, CH2). 
13C NMR (DMSO-d6): δ = 161.8, 149.8, 142.4, 137.2, 
133.5, 128.8, 128.2, 127.3, 127.2, 126.8, 125.9, 122.3, 119.8, 119.7, 110.2, 109.6, 99.7, 
29.0. MS (EI, 70 eV): m/z (%) = 310 (6, M
+), 308 (14, M
+), 273 (100). IR (KBr) ν, cm
−1: 
3419, 1661, 1617, 1490, 1466, 1398, 1235, 1048, 868, 743, 693. HRMS: calcd. for 
C18H13ClN2O: 308.0711, found: 308.0716. 
4-(2-Chlorobenzyl)-2,5-dimethyl-2,5-dihydro-3H-pyrido[4,3-b]indol-3-one (6) 
A solution of the pyrido[4,3-b]indol-3-one 4  (63  mg, 0.21  mmol) and potassium tert-
butoxide (27 mg, 0.23 mmol) in 5 ml anhydrous dimethyl sulfoxide was warmed at 80 °C 
with stirring, and after 30 min cooled to r.t. again. Then iodomethane (178 mg, 1.26 mmol) 
was added and the mixture stirred at 80 °C for 2 h. The mixture was poured on 5 ml 
aqueous ammonia (10%), and water (50 ml) was added, followed by extraction with ethyl 
acetate (3 × 40 ml). The combined organic layers were dried over magnesium sulfate and 
evaporated. The residue was purified by chromatography (ethyl acetate, ethanol, 9:1) to 
yield 6 as yellow crystals (17 mg, 24%); mp 210 °C. 
1H NMR (DMSO-d6): 8.70 (s, 1 H, 1-
H), 7.85 (d, 1 H, J = 7.8 Hz, 9-H), 7.50 (dd, 1 H, J = 7.6, 1.3 Hz, 5'-H), 7.33 (ddd, 1 H, J = 
7.8, 7.3, 1.0 Hz, 7-H), 7.28 (d, 1 H, J = 7.8 Hz, 6-H), 7.23 (ddd, 1 H, J = 7.6, 7.5, 1.3 Hz, 4'-
H), 7.17 (ddd, 1 H, J = 7.8, 7.3, 1.0 Hz, 8-H), 7.14 (ddd, 1 H, J = 7.6, 7.5, 1.3 Hz, 3'-H), 
6.82 (dd, 1 H, J = 7.6, 1.3 Hz, 2'-H), 4.32 (s, 2 H, CH2), 3.62 (s, 3 H, N
2-CH3), 3.50 (s, 3 H, 
N
5-CH3). 
13C NMR (DMSO-d6): δ = 161.1, 147.3, 142.6, 137.8, 131.7, 130.0, 128.1, 128.0, 
126.7, 126.4, 125.1, 120.7, 119.5, 117.9, 108.1, 108.0, 99.9, 37.1, 29.5, 27.2. MS (EI, 70 
eV): m/z (%) = 338 (6, M
+), 336 (20, M
+), 301 (100). IR (KBr) ν, cm
−1: 3427, 3054, 2924, 
1705, 1665, 1611, 1588, 1560, 1469, 1442, 1279, 1240, 1089, 1048, 747. HRMS: calcd. 
for C20H17ClN2O: 336.1032, found: 336.1029. 
MTT assay 
A solution of the substance in dimethyl sulfoxide (1 μl, concentrations in the range from 
10
−9 to 
−4 mol/l) was incubated with 99 μl of a suspension of HL 60 cells (9 × 10
5 cells/ml) 
in RPMI 1640 medium (PAA Laboratories) with 10% FKS in 96 well plates for 24 h. Then, 
10 μl of a solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in 
PBS (5 mg/ml) were added and the plate was incubated for another 2 h. The cells were 
quenched with 190 μl dimethyl sulfoxide and after a few min, the plates were evaluated on 
a Dynatech MRX at a wavelength of 570 nm; the reference wavelength was 630 nm [26]. 
The experiments were performed in triplicate. 
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Agar diffusion assay 
The microorganisms listed in Table 1 were cultivated on AC agar (Aldrich), except 
Aspergillus niger, which was cultivated on potato dextrose broth agar (Aldrich). Paper 
discs (6 mm diameter) were impregnated with 100 μg of each test substance or 50 μg of 
the reference drugs and placed on the agar. The bacteria media were incubated for 24 h at 
32 °C, the fungi media for 48 h at 28 °C. The diameters of the zones of inhibition were 
measured manually. The experiments were performed in triplicate. 
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